ArticleJournal of controlled release : official journal of the Controlled Release Society2012
Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 87 citations in OpenAlex.
- Subtype-specific clinical significance of RRM1 and RRM2 expression in non-small cell lung cancer: a TCGA-based analysis.Genes & genomics · 2026Article
- The Potential of Noncoding RNAs-siRNAs in Cancer Research and Therapy: Challenges and Solutions.Experientia supplementum (2012) · 2026Review
- Advancing Head and Neck Cancer Therapies: From Conventional Treatments to Emerging Strategies.Biomedicines · 2025Review
- Reprogramming the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma: Therapeutic Targets and Innovations.Oncology research · 2025Review
- Nanotechnology in the perioperative treatment of head and neck cancer: application and outlook.Frontiers in bioengineering and biotechnology · 2025Review
- The potential of ribonucleotide reductase M2 as a novel prognostic maker and therapeutic target to inhibit medulloblastoma proliferation, migration, and invasiveness.Pediatric discovery · 2024Article
- Exosomes: a review of biologic function, diagnostic and targeted therapy applications, and clinical trials.Journal of biomedical science · 2024Review
- Advances in Chitosan-based Drug Delivery Systems in Melanoma: A Narrative Review.Current medicinal chemistry · 2024Review
- Revolutionizing head and neck squamous cell carcinoma treatment with nanomedicine in the era of immunotherapy.Frontiers in immunology · 2024Review
- Improvement of variables interpretability in kernel PCA.BMC bioinformatics · 2023Article
- Review
- An innovative gene expression modulating strategy by converting nucleic acids into HNC therapeutics using carrier-free nanoparticles.Frontiers in immunology · 2023Article
- Local and Systemic Delivery of the BimS Gene Nano-Complex for Efficient Oral Squamous Cell Carcinoma Therapy.International journal of nanomedicine · 2022Article
- Clinical Advances of siRNA-Based Nanotherapeutics for Cancer Treatment.Pharmaceutics · 2021Review
- Review
- Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells.Biomolecules · 2020Article
- Knockdown of ribonucleotide reductase regulatory subunit M2 increases the drug sensitivity of chronic myeloid leukemia to imatinib‑based therapy.Oncology reports · 2019Article
- Identification of Potential Biomarkers in Glioblastoma through Bioinformatic Analysis and Evaluating Their Prognostic Value.BioMed research international · 2019Article
- siRNA Knockdown of RRM2 Effectively Suppressed Pancreatic Tumor Growth Alone or Synergistically with Doxorubicin.Molecular therapy. Nucleic acids · 2018Article
- The therapeutic effect in gliomas of nanobubbles carrying siRNA combined with ultrasound-targeted destruction.International journal of nanomedicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
Systemic delivery of siRNA to solid tumors remains challenging. In this study, we investigated the systemic delivery of a siRNA nanoparticle targeting ribonucleotide reductase subunit M2 (RRM2), and evaluated its intratumoral kinetics, efficacy and mechanism of action. Knockdown of RRM2 by an RNAi mechanism strongly inhibited cell growth in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) cell lines. In a mouse xenograft model of HNSCC, a single intravenous injection led to the accumulation of intact nanoparticles in the tumor that disassembled over a period of at least 3days, leading to target gene knockdown lasting at least 10days. A four-dose schedule of siRNA nanoparticle delivering RRM2 siRNA targeted to HNSCC tumors significantly reduced tumor progression by suppressing cell proliferation and inducing apoptosis. These results show promise for the use of RRM2 siRNA-based therapy for HNSCC and possibly NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.